Monkeypox

Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company’s Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)

Retrieved on: 
Thursday, February 9, 2023
Research, Infection, Immunity, University of Alberta Faculty of Medicine and Dentistry, Smallpox, FCAHS, Tonix Pharmaceuticals, Vaccine, Animal, RPV, Vaccination, Primate, Monkeypox, Severe acute respiratory syndrome coronavirus 2, Faculty, Virus, Monkeypox virus, University, Professor, Dentistry, Medicine

CHATHAM, N.J, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled, “Single Dose of Recombinant Chimeric Horsepox Virus (TNX‐801) Vaccination Protects Macaques from Lethal Monkeypox Challenge,” in the journal Viruses. The publication demonstrates that a single dose vaccination with TNX‐801 was effective at protecting non-human primates from infection with monkeypox virus. The article can be accessed online at https://www.mdpi.com/1999-4915/15/2/356.

Key Points: 
  • The publication demonstrates that a single dose vaccination with TNX‐801 was effective at protecting non-human primates from infection with monkeypox virus.
  • “The global monkeypox outbreak that started in the spring of 2022 reinforced the importance of protecting the population using live virus vaccines,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • “Consequently, there is a need for an effective and safer, single dose, live replicating vaccine against monkeypox virus.
  • Synthetic horsepox virus is the basis for the Company’s TNX-801 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2.

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

Retrieved on: 
Wednesday, February 8, 2023
Biotechnology, Immunotherapy, Cancer, CEF, Bioreactor, Vaccine, BIO, Infection, Conference, Smallpox, Monkeypox, MVA, Cell, GeoVax

ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced significant progress in developing a high-yield, high-capacity, continuous avian cell line system for manufacturing its MVA (modified vaccinia Ankara)-based vaccines and immunotherapies. 

Key Points: 
  • ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced significant progress in developing a high-yield, high-capacity, continuous avian cell line system for manufacturing its MVA (modified vaccinia Ankara)-based vaccines and immunotherapies.
  • Currently, MVA vaccines are manufactured in cells cultured from chicken embryonic fibroblasts (CEF), a suboptimal and time-consuming process useful primarily for niche markets and stockpile reserves.
  • Now, after exploring various approaches to growing MVA in continuous cell lines in bioreactors more suitable for high-yield, commercial-scale manufacturing, GeoVax will accelerate activities towards fully implementing a proprietary, continuous cell line manufacturing system that will provide lower-cost, scalable versatility for broad MVA vaccine and immunotherapy applications.
  • We believe that GeoVax will be the first supplier of MVA-based vaccines to implement such a transformative manufacturing process.

Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference

Retrieved on: 
Friday, February 3, 2023
Prader–Willi syndrome, Long COVID, Psychiatry, IR, CNS, Disease, Failure, MDD, COVID-19, Security (finance), Smallpox, Cancer, Government, Infection, BIO, Therapy, Orphan drug, RPV, Fibromyalgia, Conference, SL, Central nervous system, Breakthrough therapy, Monkeypox, CD40L, FDA, Hydrogen chloride, Risk, Neurology, Autoimmunity, Degenerative disease, Research, Pain, Annual report, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.

Key Points: 
  • CHATHAM, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.
  • The Company’s pre-recorded presentation will be made available during the conference to registered conference participants through the BIO CEO & Investor Conference website at https://www.bio.org/events/bio-ceo-investor-conference/sessions.
  • Beginning February 9, 2023, the presentation will also be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com .
  • Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

Retrieved on: 
Wednesday, February 1, 2023
Vaccine, Family, Human, Smallpox, Integration, Blood, Epidemic, Animal, Korea Disease Control and Prevention Agency, BWV, Patient, National Institute of Allergy and Infectious Diseases, Monkeypox, Partnership, WHO, MVD, Marburg virus disease, World Health Organization, Infection, Research, Water, IBT, Pharmaceutical industry

CINCINNATI, Ohio, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc. (“AbVacc”) for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease (“MVD”).

Key Points: 
  • CINCINNATI, Ohio, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced a collaboration with AbVacc, Inc. (“AbVacc”) for the joint development of vaccine candidates targeting monkeypox and Marburg virus disease (“MVD”).
  • BWV previously announced plans to explore a novel monkeypox vaccine candidate using this platform and under this agreement, AbVacc & BWV plan to work collaboratively to optimize the vaccine design and conduct preclinical immunogenicity and efficacy studies.
  • In addition to monkeypox vaccine development, AbVacc will utilize its extensive expertise in MVD to develop a novel vaccine targeting Marburg virus using BWV’s VLP platform.
  • There are two vaccines approved for prevention of monkeypox disease in the United States, but limited availability of either vaccine resulted in increased spread of monkeypox within the U.S. and internationally.

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Monday, January 30, 2023
Prader–Willi syndrome, Long COVID, Psychiatry, CNS, Disease, Failure, MDD, COVID-19, Security (finance), Smallpox, Cancer, Government, Infection, Therapy, Orphan drug, RPV, Fibromyalgia, SL, Central nervous system, Breakthrough therapy, Monkeypox, CD40L, FDA, Hydrogen chloride, Risk, Neurology, Autoimmunity, Degenerative disease, Annual report, Research, Pain, Letter, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Key Points: 
  • CHATHAM, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
  • On January 27, 2023, Tonix received a letter from The Nasdaq Stock Market LLC stating that because Tonix’s shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days, Tonix’s stock had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.
  • Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022 and expects interim data in the third quarter of 2023.

Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 2nd Wnt & β-catenin Targeted Drug Development Conference

Retrieved on: 
Thursday, January 26, 2023
Prader–Willi syndrome, Long COVID, Virus, Pandemic, Psychiatry, CNS, Disease, Peroxisome, MDD, COVID-19, Failure, Coronavirus, Security (finance), Smallpox, University of Alberta, Cancer, Government, Infection, Cell biology, Therapy, Degenerative disease, Orphan drug, RPV, University, Drug development, Fibromyalgia, Conference, SL, Central nervous system, Breakthrough therapy, WNT, Monkeypox, CD40L, FDA, Severe acute respiratory syndrome coronavirus 2, Hydrogen chloride, Risk, Neurology, Autoimmunity, Professor, Research, Pain, Annual report, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

Tonix has previously announced that it exercised an option to license the antiviral technology platform.

Key Points: 
  • Tonix has previously announced that it exercised an option to license the antiviral technology platform.
  • A copy of the presentation is available on the Tonix Pharmaceuticals corporate website at www.tonixpharma.com .
  • As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Tonix Pharmaceuticals Announces Publication of Paper in Antiviral Research Highlighting the Company’s Development of Monoclonal Antibody Therapeutics for Monkeypox and Smallpox

Retrieved on: 
Tuesday, January 24, 2023
Antibody, Syncytium, Infection, Pandemic, Smallpox, Tonix Pharmaceuticals, Vaccine, Therapy, Membrane protein, Antiviral Research, Monkeypox, Phenotype, Monkeypox virus, Cell, Disease, Vaccinia, Research, RDC

The publication describes the development and optimization of two high-content image-based assays that were employed to screen for potential therapeutic antibodies against the monkeypox virus using surrogate poxviruses such as vaccinia virus.

Key Points: 
  • The publication describes the development and optimization of two high-content image-based assays that were employed to screen for potential therapeutic antibodies against the monkeypox virus using surrogate poxviruses such as vaccinia virus.
  • The article highlights Tonix’s TNX-3400 platform, which includes antibodies to potentially prevent or treat monkeypox and smallpox.
  • “The RDC greatly enhances our ability to advance development of our pipeline of vaccines and therapeutics for infectious diseases.
  • We believe this technology will allow us to identify combination therapies for monkeypox and smallpox viruses which was difficult to achieve before.

Government of Canada supports wastewater monitoring for COVID-19 in Atlantic Canada

Retrieved on: 
Tuesday, January 17, 2023
Atlantic Canada, Infection, Hospital Insurance and Diagnostic Services Act, University, Community, COVID-19, Public Health Agency of Canada, University of Prince Edward Island, The Honourable, Atlantic Veterinary College, City, Indigenous self-government in Canada, NML, Science, National Microbiology Laboratory, AVC, Public Health Agency, Public health surveillance, PHAC, Poliovirus, UPEI, Monkeypox, Animal, Pharmaceutical industry, Vaccine, Atlantic Ocean, Health

Wastewater data is an important early warning sign for public health action and decisions for the benefit of communities in Atlantic Canada.

Key Points: 
  • Wastewater data is an important early warning sign for public health action and decisions for the benefit of communities in Atlantic Canada.
  • Wastewater monitoring has been essential in COVID-19 monitoring and is one of the key tools guiding the future of public health surveillance.
  • The Government of Canada has committed $28.1 million since May 2020 to establish, expand and enhance the pan-Canadian wastewater surveillance program.
  • "Wastewater monitoring is the future of public health surveillance for infectious diseases in Canada.

Hybribio returns to Medlab Middle East 2023

Retrieved on: 
Tuesday, January 17, 2023
Transfer, HPV, Public Health Emergency of International Concern, COVID-19, Colorectal cancer, Laboratory, Cervical cancer, Monkeypox, Methylation, STD, Public health emergency, PCR, Bladder cancer, Monkeypox virus, World Trade Center, Thalassemia, PHEIC, Vaccine

GUANGZHOU, China, Jan. 17, 2023 /PRNewswire/ -- Medlab Middle East 2023 will be held at the World Trade Centre, Dubai, UAE from February 6 to 9.

Key Points: 
  • GUANGZHOU, China, Jan. 17, 2023 /PRNewswire/ -- Medlab Middle East 2023 will be held at the World Trade Centre, Dubai, UAE from February 6 to 9.
  • Due to the COVID-19 pandemic, Hybribio (300639.SZ) was absent from Medlab Middle East for the last three years.
  • This year, Hybribio returns to the Medlab Middle East with varieties of cutting-edge in-vitro diagnostic products and latest nucleic acid molecular testing solutions, covering HPV, STD, thalassemia, methylation (cervical cancer, bladder cancer, colorectal cancer) etc.
  • Hybribio (300639.SZ) looks forward to meeting you at the Medlab Middle East 2023 and sincerely invites you to visit our booth to explore the future of nucleic acid testing!

Hybribio returns to Medlab Middle East 2023

Retrieved on: 
Tuesday, January 17, 2023
Transfer, HPV, Public Health Emergency of International Concern, COVID-19, Colorectal cancer, Laboratory, Cervical cancer, Monkeypox, Methylation, STD, Public health emergency, PCR, Bladder cancer, Monkeypox virus, World Trade Center, Thalassemia, PHEIC, Vaccine

GUANGZHOU, China, Jan. 17, 2023 /PRNewswire/ -- Medlab Middle East 2023 will be held at the World Trade Centre, Dubai, UAE from February 6 to 9.

Key Points: 
  • GUANGZHOU, China, Jan. 17, 2023 /PRNewswire/ -- Medlab Middle East 2023 will be held at the World Trade Centre, Dubai, UAE from February 6 to 9.
  • Due to the COVID-19 pandemic, Hybribio (300639.SZ) was absent from Medlab Middle East for the last three years.
  • This year, Hybribio returns to the Medlab Middle East with varieties of cutting-edge in-vitro diagnostic products and latest nucleic acid molecular testing solutions, covering HPV, STD, thalassemia, methylation (cervical cancer, bladder cancer, colorectal cancer) etc.
  • Hybribio (300639.SZ) looks forward to meeting you at the Medlab Middle East 2023 and sincerely invites you to visit our booth to explore the future of nucleic acid testing!